Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 550 of 3284 entries
View as:

Safety, Tolerability & PK of AZD0328 in Caucasian & Japanese

Phase: N/A Priority: Normal
NCT ID: NCT00738959 Org: User:
Start: 06/30/08 End: 10/31/08 Due: 10/31/09

T790M Plasma Testing Methodology Comparison and Clinical Validation

Phase: N/A Priority: Normal
NCT ID: NCT02997501 Org: User:
Start: 12/23/16 End: 10/24/18 Due: 10/24/19

Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT01471171 Org: User:
Start: 11/30/11 End: 06/30/12 Due: 06/30/13

Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Phase: N/A Priority: Normal
NCT ID: NCT02273050 Org: User:
Start: 12/31/14 End: 08/31/16 Due: 08/31/17

Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Phase: N/A Priority: Normal
NCT ID: NCT01120093 Org: User:
Start: 05/31/10 End: 08/31/10 Due: 08/31/11

National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria

Phase: N/A Priority: Normal
NCT ID: NCT02725892 Org: User:
Start: 07/19/16 End: 02/28/21 Due: 02/28/22

Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02436577 Org: User:
Start: 06/30/15 End: 08/31/15 Due: 08/31/16

Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

Phase: N/A Priority: Normal
NCT ID: NCT00972244 Org: User:
Start: 08/31/09 End: 05/31/10 Due: 05/31/11

FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study

Phase: N/A Priority: Normal
NCT ID: NCT02984423 Org: User:
Start: 12/27/16 End: 06/30/19 Due: 06/30/20

AZD3293 Thorough QT Study in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02040987 Org: User:
Start: 01/31/14 End: 05/31/14 Due: 05/31/15

SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT00206115 Org: User:
Start: 11/30/04 End: 12/31/05 Due: 12/31/06

Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention

Phase: N/A Priority: Normal
NCT ID: NCT00689377 Org: User:
Start: 05/31/07 End: 07/31/08 Due: 07/31/09

Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00296387 Org: User:
Start: 01/31/06 End: 10/31/07 Due: 10/31/08

Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT01392807 Org: User:
Start: 07/31/11 End: 11/30/11 Due: 11/30/12

A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.

Phase: N/A Priority: Normal
NCT ID: NCT03971110 Org: User:
Start: 01/28/21 End: 11/09/22 Due: 11/09/23

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT01933932 Org: User:
Start: 09/25/13 End: 12/31/25 Due: 12/31/26

A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

Phase: N/A Priority: Normal
NCT ID: NCT00259051 Org: User:
Start: 01/31/04 End: 08/31/04 Due: 08/31/05

IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US

Phase: N/A Priority: Normal
NCT ID: NCT05970263 Org: User:
Start: 01/19/24 End: 12/31/25 Due: 12/31/26

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.

Phase: N/A Priority: Normal
NCT ID: NCT05662033 Org: User:
Start: 12/05/22 End: 10/29/24 Due: 10/29/25

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Phase: N/A Priority: Normal
NCT ID: NCT00372788 Org: User:
Start: 08/31/06 End: 12/31/08 Due: 12/31/09

Study to Assess the Bioequivalence Between D961S and Esomeprazole/Buffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01494402 Org: User:
Start: 01/31/12 End: 03/31/12 Due: 03/31/13

Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

Phase: N/A Priority: Normal
NCT ID: NCT00303524 Org: User:
Start: 02/28/06 End: 02/28/09 Due: 02/28/10

Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion

Phase: N/A Priority: Normal
NCT ID: NCT01275781 Org: User:
Start: 01/31/11 End: 02/28/11 Due: 02/28/12

HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

Phase: N/A Priority: Normal
NCT ID: NCT06125314 Org: User:
Start: 03/05/24 End: 09/30/24 Due: 09/30/25

AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

Phase: N/A Priority: Normal
NCT ID: NCT03317002 Org: User:
Start: 10/30/17 End: 04/08/20 Due: 04/08/21